Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Jade Biosciences, Inc. (JBIO)
Company Research
Source: Yahoo! Finance
with IgA nephropathy expected to begin mid-2026 with preliminary data anticipated in 2027 JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, expected to advance into first-in-human clinical trial in rheumatoid arthritis patients in the second quarter of 2026; interim data anticipated in 2027 Third development candidate, JADE301, nominated; Phase 1 clinical trial expected to commence in the first half of 2027 $336 million of cash, cash equivalents, and investments as of December 31 st , 2025 expected to provide runway into the first half of 2028 SAN FRANCISCO and VANCOUVER, British Columbia, March 06, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the fourth quarter and full year ending December 31, 2025, and provided a corporate update. Tom Frohlich, Chief Executive Officer of Jade
Show less
Read more
Impact Snapshot
Event Time:
JBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JBIO alerts
High impacting Jade Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
JBIO
News
- Jade Biosciences (JBIO) had its price target raised by HC Wainwright from $25.00 to $35.00. They now have a "buy" rating on the stock.MarketBeat
- Jade Biosciences (JBIO) had its price target raised by BTIG Research from $28.00 to $39.00. They now have a "buy" rating on the stock.MarketBeat
- Jade Biosciences (JBIO) was downgraded by Zacks Research from "hold" to "strong sell".MarketBeat
- Jade Biosciences (JBIO) had its price target raised by Guggenheim from $17.00 to $23.00. They now have a "buy" rating on the stock.MarketBeat
- Jade Biosciences (JBIO) was upgraded by William Blair to "strong-buy".MarketBeat
JBIO
Earnings
- 11/13/25 - Beat
JBIO
Sec Filings
- 3/6/26 - Form S-8
- 3/6/26 - Form POS
- 3/6/26 - Form POS
- JBIO's page on the SEC website